Crossmark

BHLHE22, targeted by deubiquitinating enzyme OTUD3, exerts an antitumor role in triple-negative breast cancer progression via transcriptionally inhibiting CDT1

Crossref DOI link: https://doi.org/10.1186/s13058-025-02198-0

Published Online: 2026-01-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jiang, Lei

Xu, Junnan

Jiang, Cui

Jia, Yufeng

Zhang, Ye

Sun, Tao
License Information

Text and Data Mining valid from 2026-01-02

Version of Record valid from 2026-01-15
More Information

Article History

Received: 26 August 2025

Accepted: 4 December 2025

First Online: 2 January 2026

Declarations

:

: The use and care of animals in this study is approved by the ethics committee of China Medical University. The informed consents were obtained from all participants. All human experiments were approved by the Ethics Committee of Liaoning Cancer Hospital.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below